News | May 05, 2014

First Patient Enrolled in Gore TAG Thoracic Branch Endoprosthesis LSA Feasibility Study

Multi-Center study to assess feasibility of Gore Device to treat historically challenging patient population

Gore Tag Thoracic Branch Endoprosthesis LSA Feasibility Study Clinical Trial

May 5, 2014 — W. L. Gore & Associates (Gore) announced that Himanshu Patel, M.D. and David Williams, M.D. at The University of Michigan enrolled the first patient in the Gore TAG Thoracic Branch Endoprosthesis LSA Feasibility Study, a U.S.-based, multi-center feasibility trial. The Food and Drug Administration (FDA) approved the investigational device exemption (IDE) trial for the Gore TAG Thoracic Branch Endoprosthesis in the treatment of thoracic aortic aneurysms that require coverage of the left subclavian artery (LSA).

“Thoracic aortic aneurysms that encroach on the LSA make treating these challenging anatomies very difficult, leaving physicians no choice but to use more invasive surgical techniques or to cover the branch vessel,” said Patel. “Using the Gore TAG Thoracic Branch Endoprosthesis, we were able to successfully treat the first patient in the study using endovascular means only. These results demonstrate the feasibility of using branched stent-grafts to treat aortic aneurysms that involve the LSA.”

“With this study, we hope to demonstrate that the Gore device allows physicians to safely treat aortic aneurysms near the aortic arch while maintaining blood flow to all branch vessels using endovascular techniques,” said Michael Dake, M.D., principal investigator and Thelma and Henry Doelger Professor of Cardiovascular Surgery at the Stanford School of Medicine, Stanford, Calif. “Gore’s device will reduce the need for invasive surgical procedures commonly required today, thus reducing the complications associated with treatment of this complex disease.”

The Gore TAG Thoracic Branch Endoprosthesis builds on more than 15 years of Gore experience in aortic innovation. Designed for long-term durability, the device allows for femoral-only access over a pre-positioned branch guidewire for ease of implantation. The device also features the CARMEDA BioActive Surface (CBAS Heparin Surface) for sustained anti-thrombotic bioactivity, as is present on many of Gore’s peripheral vascular products.

Gore accomplished several key regulatory milestones in 2013. The Gore Excluder Iliac Branch Endoprosthesis received CE mark in October 2013 and is currently available for investigational purposes only in the U.S. Additionally, the FDA approved the Conformable Gore TAG Thoracic Endoprosthesis for the treatment of acute and chronic dissections, making it the first and only stent-graft that is FDA approved to treat aneurysms, traumatic transections, and dissections of the thoracic aorta.

For more information: www.gore.com

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Overlay Init